The company crushed analyst profitability estimates, both for its trailing quarter and for its full-year guidance.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $54.8, a ...

A Relative Strength Rating upgrade for Collegium Pharmaceutical shows improving technical performance. Will it continue?

Recent discussions on X about Recursion Pharmaceuticals (RXRX) have centered around the company's notable stock price surge of 14% over the past month, a performance that stands out against a ...

West Pharmaceutical's high-value product mix is expanding, driving margin growth through proprietary. See why I rate WST ...

Rani Therapeutics stock surged 200% after securing a $1 billion partnership with Chugai and raising $60 million in funding.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Not just any pharmaceutical stock will do, though. They aren't all created equal. Let's discuss two leaders in the industry ...

Over the past decade, pharmaceutical maker Pfizer ( PFE -0.53%) has severely lagged the market. Dividends reinvested aside, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Stay up-to-date with the Sun Pharma Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on ...